Interim results from the Phase 3 DASL-HiCaP trial show that adding darolutamide to standard androgen deprivation therapy (ADT) and radiation therapy reduces the risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence. The 4-year metastasis-free survival rate was 95% with darolutamide versus 88% with placebo. Secondary endpoints also improved, and the safety profile was consistent with previous studies. These findings, presented at the ESMO Congress 2026, suggest darolutamide could become an important addition to early prostate cancer treatment, with ongoing follow-up to assess long-term survival outcomes.
Darolutamide's impact on prostate cancer patients at high risk of recurrence is highlighted by a 58% reduction in the risk of metastasis or death. For readers following the health sector, here is Pluang's market snapshot as of Oct 24, 2026 13:41 WIB: out of 150 priced US health stocks, 44 rose and 105 fell. Notable movers include LQDA at USD 42.65 (+7.46%, typical hold time 2 days, 56% buy orders), OSCR at USD 30.99 (-6.99%, typical hold time 16 days, 58% sell orders), and INO at USD 0.90 (+6.94%, typical hold time 43 days, 51% sell orders).
Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...
Google cleared 816 acres of forest in Northern Finland without full environmental approval to build a data center, cutting down about 250,000 trees. This caused ecological damage, forcing wolves closer to towns and polluting local waterways, which an...
PJT Partners is rated a Buy due to its strong position in restructuring and secondary transactions, which provide resilience amid a slowdown in mergers and acquisitions (M&A) and primary fundraising. Rising credit risks in AI infrastructure could tri...
Trader Killa highlighted that Bitcoin (BTC) still has room to move higher in the market. He warned that traders who rely heavily on leverage and chase short-term price swings might miss out on a sustained upward trend. Killa criticized those who freq...
In early November, Sui will unlock a tranche of tokens ranging from 2.07 million to 22.6 million SUI, representing up to 0.55% of the circulating supply. This unlock is part of a long-term vesting schedule with a 12-month cliff and 72 months of linea...
